Clinical Data Novo says high-dose Wegovy can cause 28% weight loss PharmaphorumNovo Nordisk has built the case for migration to its 'triple-dose' version of injectable GLP-1 Wegovy with new weight-loss and body composition data.Metabolic & GLP-1Read full story pharminent May 12, 2026 (Last updated: May 12, 2026) Pharmaphorum Novo Nordisk has built the case for migration to its ‘triple-dose’ version of injectable GLP-1 Wegovy with new weight-loss and body composition data. Metabolic & GLP-1 Read full story Post navigation Previous: A year after Vertex’s big launch, pain drug research faces a pivotal momentNext: FDA turns to old drugs to address new diseases, persistent medical needs Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
